Stock Symbol ARNA: A Comprehensive Guide to the Company

ARNA, the stock symbol for AstraZeneca's respiratory and inflammation business, was spun off from the larger pharmaceutical company in 1993.

AstraZeneca's respiratory and inflammation business was a significant contributor to the company's overall revenue, with a strong portfolio of products that included Symbicort and Pulmicort.

ARNA's focus on respiratory and inflammation diseases has allowed the company to develop a deep understanding of these complex conditions and to create innovative treatments that address them.

The company's pipeline includes a range of promising therapies, including a monoclonal antibody for the treatment of severe asthma.

Arena Pharmaceuticals, Inc. (ARNA) has been making waves in the pharmaceutical industry. Pfizer completed its $6.7 billion acquisition of ARNA on March 10, 2022, valuing shares at $100 each.

ARNA stock has seen significant trading volume, with 7 million shares on the move on the day of the Pfizer news. This is a notable jump from the company's daily average trading volume of about 498,000 shares.

The acquisition brings many advantages to Pfizer, including Arena's various therapeutic candidates in developmental stages. Pfizer plans to accelerate the clinical development of etrasimod for patients with immuno-inflammatory diseases.

Arena Pharmaceuticals, or ARNA, is rocketing today due to a massive deal with Pfizer. Pfizer is acquiring Arena Pharmaceuticals for $6.7 billion, valuing shares of ARNA stock at $100 each.

This is a huge jump from the closing price of the stock on Friday. The deal was announced on March 11, 2022, and is expected to be completed after customary closing conditions are met.

Pfizer is using cash on hand to fund the transaction, and the acquisition is expected to bring many advantages to the company. This includes the addition of Arena Pharmaceuticals' various therapeutic candidates that are still in developmental stages.

The acquisition is a significant move for Pfizer, and the company is planning to accelerate the clinical development of etrasimod for patients with immuno-inflammatory diseases. Mike Gladstone, global president and general manager of Inflammation and Immunology at Pfizer, made a statement about the deal, highlighting the potential benefits of the acquisition.

ARNA stock is seeing heavy trading today, with over 7 million shares on the move. This is a significant jump from the company's daily average trading volume of about 498,000 shares.

Arena Pharmaceuticals Inc. traded at a new 12-month high of $100.00, with approximately 748,000 shares changing hands today.

This is a significant increase from the average 30-day volume of 1.4 million shares.

The company's stock price has been on the rise, and it's worth noting that this is a new high for Arena Pharmaceuticals Inc.

The S&P 500 futures retreated this morning, down by -0.18%, after crude prices jumped more than +4%.

This shift in the market may have an impact on the stock prices of pharmaceutical companies like Arena Pharmaceuticals Inc.

Arena Pharmaceuticals Inc. will release its fourth quarter and full-year 2021 financial results on Wednesday, February 23, 2022, after the close of the U.S. markets.

The company's financial results will provide valuable insights into its performance and future prospects.

The Compensation Committee of Arena Pharmaceuticals Inc.'s Board of Directors granted 18 new employees 18,527 inducement restricted stock units, and later granted 16 new employees 28,659 inducement restricted stock units.

Lamine Mbow serves as the Chief Technology/Science/Research and Development Officer at Arena Pharmaceuticals, a role he took on in September 2021.

Douglas Bakan previously held the same position as Lamine Mbow at Arena Pharmaceuticals, but the exact date of his departure is not specified.

Margaret M. Madden is the Corporate Secretary at Arena Pharmaceuticals, a position she has held for an undisclosed duration.

The share price of ARNA has been on a rollercoaster ride in recent times. As of the latest data, the open price was $263.70, with a 1-day change of -$3.80, which is a -1.44% decrease.

The monthly price history for ARNA shows a significant increase, with a 1-month change of $27.40, or 11.81%. This is a notable uptick in the stock's value.

Here's a breakdown of the stock's performance over different time periods:

The stock's volume has been significant, with a 1-month volume of 273,731 shares. This suggests a decent level of trading activity in the stock.

It's worth noting that the 52-week high for ARNA was $285.00, while the 52-week low was $162.00. This indicates a significant range in the stock's price over the past year.

The Resistance level for ARNA is currently at $279.63, while the Support level is at $253.68. These levels can be useful for traders looking to identify potential buying or selling opportunities.

Several analysts have recently downgraded Arena Pharmaceuticals, the company behind the stock symbol ARNA.

HC Wainwright downgraded Arena Pharmaceuticals to Neutral From Buy, with a price target of $100.

Cantor Fitzgerald also downgraded Arena Pharmaceuticals to Neutral From Overweight, adjusting its price target to $100 from $93.

Citigroup downgraded Arena Pharmaceuticals to Neutral From Buy, adjusting its price target to $100 from $101.

Needham downgraded Arena Pharmaceuticals to Hold From Buy, dropping its price target to $80.

Credit Suisse downgraded Arena Pharmaceuticals to Neutral from Outperform, raising its price target to $100 from $98.

Here's a summary of the price target adjustments: